Compare Ginkgo Bioworks Holdings Inc (DNA) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Moody's Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Moody's Corporation trades at $464.23 (market cap $79.44B). The key difference: Moody's Corporation is far larger — about 104× Ginkgo Bioworks Holdings Inc's market cap, and Moody's Corporation pays a 0.9% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Moody's Corporation for 132 Days on average.
| DNA | MCO | |
|---|---|---|
Market Cap | $763.64M | $79.44B |
Volume | 3,204,177 | 526,684 |
Sector | Health | Financials |
52-Week High | $15.83 | $539.61 |
52-Week Low | $5.48 | $412.23 |
Typical Hold Time | 7 Days | 132 Days |
Enterprise Value | $865.59M | $85.46B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with a negative net income margin of -219.6%. Recent news includes a partnership with TuneLab and a $17.5 million ARPA-H subcontract.
The outlook is challenged by persistent losses and negative cash flow, though strategic partnerships offer growth potential. Analyst sentiment is divided evenly between buy, hold, and sell ratings. Key risks include execution on profitability and high cash burn. The stock presents a speculative opportunity dependent on the company's ability to monetize its technology platform.
MCO trades at $458.69, up 2.01% today, with a bearish technical signal but strong fundamentals including 34.25% net income margin and 80.15% ROE. Recent earnings beats and a consensus price target of $536.40 suggest upside potential. The company announced a minority stake in PhilRatings and a new credit risk model with Allvue, expanding its Asia-Pacific presence and product offerings.
Outlook is positive given consistent earnings growth and strategic expansions, though high valuation multiples and bearish technical indicators near-term pose risks. Analyst consensus is bullish with 56% buy ratings, but investors should monitor debt levels and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
